TriSalus Life Sciences to Participate in Upcoming September Investor Conferences
TLSIWESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the foll
TriSalus Life Sciences Reports Second Quarter 2025 Results and Reiterates 2025 Guidance
TLSIDENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended June 30, 2025, and provides an operational update. “TriSalus continued to deliver strong commercial momentum in the second quarter, underscoring the growing clinical ado
TriSalus Life Sciences Announces Publication of Safety and Efficacy Results for a Novel Pressure-Enabled Thyroid Embolization Technique
TLSIWESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, is pleased to announce the publication of clinical data evaluating the use of its proprietary Pressure-Enabled Drug DeliveryTM (PEDDTM) technology in thyroid parenchymal embolization, a new application for the treatment of patients with sympt
TriSalus Life Sciences Appoints David Patience As CFO, Effective Jul. 1
TLSITriSalus Life Sciences confirming FY 2025 guidance of at least 50% revenue growth.
TLSITriSalus Life Sciences Q1 EPS $(0.39) Misses $(0.23) Estimate, Sales $9.17M Beat $9.04M Estimate
TLSITriSalus Life Sciences Says Prelim. Q1 Results Show ~$9.2M In Revenue, Driven By TriNav Infusion System
TLSITriSalus Life Sciences Announces $22M Private Placement Of 5.5M Shares Of Common Stock At A Price Of $4/Share
TLSITrisalus Life Sciences Secures $22M In Securities Purchase Agreement For Common Stock
TLSICanaccord Genuity Maintains Buy on TriSalus Life Sciences, Maintains $11 Price Target
TLSITriSalus Reaffirms 2025 Guidance Of Greater Than 50% Revenue Growth, Greater Than 20% Reduction In Operating Expenses, Positive EBITDA And Positive Cash Flow In H2 2025
TLSITriSalus Life Sciences Q4 2024 GAAP EPS $(0.40) Misses $(0.32) Estimate, Sales $8.26M Beat $8.12M Estimate
TLSIExamining the Future: TriSalus Life Sciences's Earnings Outlook
TLSITrisalus Life Sciences Entered A $50M, Five-year Credit Agreement With Orbimed, Securing $25M Upfront. An Additional $10M Is Available Until June 30, 2025, And $15M Until December 31, 2025, Contingent On Revenue Targets
TLSILake Street Initiates Coverage On TriSalus Life Sciences with Buy Rating, Announces Price Target of $10
TLSITrisalus Life Sciences Announced The Publication Of Research In Journal Of Vascular And Interventional Radiology. The Preclinical Study Highlights The Performance Of The TriNav Infusion System In Delivering Embospheres Into Liver Tumors When Compared To D
TLSICanaccord Genuity Maintains Buy on TriSalus Life Sciences, Lowers Price Target to $11
TLSITriSalus Expects 2025 Sales To Grow By More Than 50%; Expects To Achieve Positive Full-year EBITDA And Positive Cash Flow In H2 Of The Year
TLSITriSalus Life Sciences Q3 Sales $7.35M Miss $7.39M Estimate
TLSI